In addition, a significant reduction in the epithelial–mesenchymal transition (EMT) biomarker Snail was exclusively observed in 4T1 tumor tissue treated with the SYRO and MET combination, also confirming its efficacy in hampering this pathway [29,30] associated with a poor prognosis in BC patients [31]. This evidence concerns the gene MET and breast cancer.